hydroxychloroquine has been researched along with Kidney Diseases in 10 studies
Hydroxychloroquine: A chemotherapeutic agent that acts against erythrocytic forms of malarial parasites. Hydroxychloroquine appears to concentrate in food vacuoles of affected protozoa. It inhibits plasmodial heme polymerase. (From Gilman et al., Goodman and Gilman's The Pharmacological Basis of Therapeutics, 9th ed, p970)
hydroxychloroquine : An aminoquinoline that is chloroquine in which one of the N-ethyl groups is hydroxylated at position 2. An antimalarial with properties similar to chloroquine that acts against erythrocytic forms of malarial parasites, it is mainly used as the sulfate salt for the treatment of lupus erythematosus, rheumatoid arthritis, and light-sensitive skin eruptions.
Kidney Diseases: Pathological processes of the KIDNEY or its component tissues.
| Excerpt | Relevance | Reference |
|---|---|---|
| " For inflammatory arthritis, 79% of experts agreed (first- through fourth-line treatments were MTX, low-dose glucocorticoids, hydroxychloroquine, and rituximab or tocilizumab, respectively)." | 3.88 | Treatment Algorithms for Systemic Sclerosis According to Experts. ( Fernández-Codina, A; Pope, JE; Walker, KM, 2018) |
| " Recommendations were made based on available data, consideration of pharmacokinetic properties (including variability), the dosing and anticipated treatment duration of each regimen in COVID-19 and known toxicities." | 2.72 | Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment. ( Back, D; Boyle, A; Burger, D; Davidson, K; El-Sherif, O; Gibbons, S; Khoo, S; Marra, F; Marzolini, C; Siccardi, M; Smolders, EJ; Sommerville, AJ, 2021) |
| "In the 1980's, pregnancies in systemic sclerosis (SSc) patients were considered to be at high risk for poor foetal and maternal outcome." | 2.44 | [Pregnancy in systemic sclerosis]. ( Bérezné, A; Mouthon, L, 2008) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 1 (10.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 2 (20.00) | 29.6817 |
| 2010's | 4 (40.00) | 24.3611 |
| 2020's | 2 (20.00) | 2.80 |
| Authors | Studies |
|---|---|
| Gougis, P | 1 |
| Fenioux, C | 1 |
| Funck-Brentano, C | 1 |
| Veyri, M | 1 |
| Gligorov, J | 1 |
| Solas, C | 1 |
| Spano, JP | 1 |
| Marra, F | 1 |
| Smolders, EJ | 1 |
| El-Sherif, O | 1 |
| Boyle, A | 1 |
| Davidson, K | 1 |
| Sommerville, AJ | 1 |
| Marzolini, C | 1 |
| Siccardi, M | 1 |
| Burger, D | 1 |
| Gibbons, S | 1 |
| Khoo, S | 1 |
| Back, D | 1 |
| Colla, L | 1 |
| Diena, D | 1 |
| Rossetti, M | 1 |
| Manzione, AM | 1 |
| Marozio, L | 1 |
| Benedetto, C | 1 |
| Biancone, L | 1 |
| Fernández-Codina, A | 1 |
| Walker, KM | 1 |
| Pope, JE | 1 |
| Sperati, CJ | 1 |
| Rosenberg, AZ | 1 |
| Sebastiani, GD | 1 |
| Prevete, I | 1 |
| Piga, M | 1 |
| Iuliano, A | 1 |
| Bettio, S | 1 |
| Bortoluzzi, A | 1 |
| Coladonato, L | 1 |
| Tani, C | 1 |
| Spinelli, FR | 1 |
| Fineschi, I | 1 |
| Mathieu, A | 1 |
| Bérezné, A | 1 |
| Mouthon, L | 1 |
| Bracamonte, ER | 1 |
| Kowalewska, J | 1 |
| Starr, J | 1 |
| Gitomer, J | 1 |
| Alpers, CE | 1 |
| Wallace, DJ | 1 |
| Harker, LA | 1 |
| Hirsh, J | 1 |
| Gent, M | 1 |
| Genton, E | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| The Effectiveness of ECP in Diffuse Cutaneous Systemic Sclerosis[NCT04986605] | Phase 2 | 15 participants (Anticipated) | Interventional | 2023-12-01 | Not yet recruiting | ||
| Pragmatic Clinical Trials in Scleroderma[NCT03610217] | 400 participants (Anticipated) | Interventional | 2018-10-31 | Not yet recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
5 reviews available for hydroxychloroquine and Kidney Diseases
| Article | Year |
|---|---|
Recommendations for Dosing of Repurposed COVID-19 Medications in Patients with Renal and Hepatic Impairment.
Topics: Adenosine Monophosphate; Alanine; Antiviral Agents; Clinical Trials as Topic; COVID-19; COVID-19 Dru | 2021 |
Immunosuppression in pregnant women with renal disease: review of the latest evidence in the biologics era.
Topics: Azathioprine; Biological Products; Calcineurin Inhibitors; Cyclophosphamide; Directive Counseling; F | 2018 |
[Pregnancy in systemic sclerosis].
Topics: Angiotensin-Converting Enzyme Inhibitors; Antirheumatic Agents; Female; Fetal Diseases; Humans; Hydr | 2008 |
Antimalarial agents and lupus.
Topics: Antibodies, Antiphospholipid; Antimalarials; Chloroquine; Female; Humans; Hydroxychloroquine; Kidney | 1994 |
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
1 trial available for hydroxychloroquine and Kidney Diseases
| Article | Year |
|---|---|
Critical evaluation of platelet-inhibiting drugs in thrombotic disease.
Topics: Arteriosclerosis; Aspirin; Blood Platelets; Cerebrovascular Disorders; Clinical Trials as Topic; Clo | 1975 |
5 other studies available for hydroxychloroquine and Kidney Diseases
| Article | Year |
|---|---|
Anticancer drugs and COVID-19 antiviral treatments in patients with cancer: What can we safely use?
Topics: Amides; Antibodies, Monoclonal, Humanized; Antineoplastic Agents; Antineoplastic Agents, Hormonal; A | 2020 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Treatment Algorithms for Systemic Sclerosis According to Experts.
Topics: Algorithms; Angiotensin Receptor Antagonists; Angiotensin-Converting Enzyme Inhibitors; Antibodies, | 2018 |
Hydroxychloroquine-induced mimic of renal Fabry disease.
Topics: Adult; Antirheumatic Agents; Biopsy; Diagnosis, Differential; Fabry Disease; Female; Humans; Hydroxy | 2018 |
Early Lupus Project - A multicentre Italian study on systemic lupus erythematosus of recent onset.
Topics: Adult; Age of Onset; Antibodies, Antinuclear; Antibodies, Antiphospholipid; Arthritis; Female; Human | 2015 |
Iatrogenic phospholipidosis mimicking Fabry disease.
Topics: alpha-Galactosidase; Antirheumatic Agents; Diagnosis, Differential; DNA Mutational Analysis; Epithel | 2006 |